Literature DB >> 21188408

Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases.

Sarah Jesse1, Johannes Brettschneider, Sigurd D Süssmuth, Bernhard G Landwehrmeyer, Christine A F von Arnim, Albert C Ludolph, Hayrettin Tumani, Markus Otto.   

Abstract

In neurodegenerative diseases, cerebrospinal fluid analysis (CSF) is predominantly performed to exclude inflammatory diseases and to perform a risk assessment in dementive disorders by measurement of tau proteins and amyloid beta peptides. However, large scale data on basic findings of CSF routine parameters are generally lacking. The objective of the study was to define a normal reference spectrum of routine CSF parameters in neurodegenerative diseases. Routine CSF parameters (white cell count, lactate and albumin concentrations, CSF/serum quotients of albumin (Q (alb)), IgG, IgA, IgM, and oligoclonal IgG bands (OCB)) were retrospectively analyzed in an academic research setting. A total of 765 patients (Alzheimer's disease (AD), Parkinson's disease (PD), Parkinson's disease dementia (PDD), vascular dementia (VD), frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), multisystem atrophy (MSA), motor neuron diseases (MND), spinocerebellar ataxia (SCA), Huntington's disease (HD)) and non-demented control groups including a group of patients with muscular disorders (MD). The main outcome measures included statistical analyses of routine CSF parameters. Mildly elevated Q (alb) were found in a small percentage of nearly all subgroups and in a higher proportion of patients with PSP, MSA, VD, PDD, and MND. With the exception of 1 MND patient, no intrathecal Ig synthesis was observed. Isolated OCBs in CSF were sometimes found in patients with neurodegenerative diseases without elevated cell counts; lactate levels were always normal. A slightly elevated Q (alb) was observed in a subgroup of patients with neurodegenerative diseases and does not exclude the diagnosis. Extensive elevation of routine parameters is not characteristic and should encourage a re-evaluation of the clinical diagnosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21188408      PMCID: PMC3101362          DOI: 10.1007/s00415-010-5876-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

Review 1.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

Authors:  H Reiber; J B Peter
Journal:  J Neurol Sci       Date:  2001-03-01       Impact factor: 3.181

Review 2.  Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics.

Authors:  Hansotto Reiber
Journal:  Restor Neurol Neurosci       Date:  2003       Impact factor: 2.406

3.  Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update.

Authors:  G Keir; R W Luxton; E J Thompson
Journal:  Ann Clin Biochem       Date:  1990-09       Impact factor: 2.057

4.  Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis.

Authors:  A Leonardi; G Abbruzzese; L Arata; L Cocito; M Vische
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

5.  Office of Rare Diseases neuropathologic criteria for corticobasal degeneration.

Authors:  D W Dickson; C Bergeron; S S Chin; C Duyckaerts; D Horoupian; K Ikeda; K Jellinger; P L Lantos; C F Lippa; S S Mirra; M Tabaton; J P Vonsattel; K Wakabayashi; I Litvan
Journal:  J Neuropathol Exp Neurol       Date:  2002-11       Impact factor: 3.685

6.  Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics.

Authors:  Rüdiger Zimmermann; Georg Beck; Sabine Knispel; Juan Manuel Maler; Markus Weih; Jens Wiltfang; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

7.  The morphology of cerebrospinal fluid drainage pathways in human arachnoid granulations.

Authors:  M L Upton; R O Weller
Journal:  J Neurosurg       Date:  1985-12       Impact factor: 5.115

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

9.  The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia.

Authors:  J C Janssen; A K Godbolt; P Ioannidis; E J Thompson; M N Rossor
Journal:  J Neurol       Date:  2004-02       Impact factor: 4.849

10.  Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature.

Authors:  Piotr Lewczuk; Hermann Esselmann; Mirko Bibl; Georg Beck; Juan Manuel Maler; Markus Otto; Johannes Kornhuber; Jens Wiltfang
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 2.866

View more
  20 in total

1.  Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.

Authors:  Claudia D Wurster; Petra Steinacker; René Günther; Jan C Koch; Paul Lingor; Zeljko Uzelac; Simon Witzel; Kurt Wollinsky; Benedikt Winter; Alma Osmanovic; Olivia Schreiber-Katz; Rami Al Shweiki; Albert C Ludolph; Susanne Petri; Andreas Hermann; Markus Otto
Journal:  J Neurol       Date:  2019-09-24       Impact factor: 4.849

Review 2.  Dementia and behavioral neurology: recent advances.

Authors:  Basar Bilgic; Hasmet A Hanagasi; Murat Emre
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

3.  Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD.

Authors:  Emily Feneberg; Petra Steinacker; Alexander Erich Volk; Jochen Hans Weishaupt; Marc Axel Wollmer; Adam Boxer; Hayrettin Tumani; Albert Christian Ludolph; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2015-12-11       Impact factor: 3.575

4.  Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies.

Authors:  Patrick Oeckl; Fabian Metzger; Magdalena Nagl; Christine A F von Arnim; Steffen Halbgebauer; Petra Steinacker; Albert C Ludolph; Markus Otto
Journal:  Mol Cell Proteomics       Date:  2016-08-09       Impact factor: 5.911

5.  Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis.

Authors:  Steffen Halbgebauer; André Huss; Mathias Buttmann; Petra Steinacker; Patrick Oeckl; Isabel Brecht; Andreas Weishaupt; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2016-03-19       Impact factor: 4.849

6.  Nanowire array chips for molecular typing of rare trafficking leukocytes with application to neurodegenerative pathology.

Authors:  Minsuk Kwak; Dong-Joo Kim; Mi-Ri Lee; Yu Wu; Lin Han; Sang-Kwon Lee; Rong Fan
Journal:  Nanoscale       Date:  2014-06-21       Impact factor: 7.790

7.  Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations.

Authors:  Nicola Ticozzi; Cinzia Tiloca; Niccolò E Mencacci; Claudia Morelli; Alberto Doretti; Daniela Rusconi; Claudia Colombrita; Davide Sangalli; Federico Verde; Palma Finelli; Stefano Messina; Antonia Ratti; Vincenzo Silani
Journal:  J Neurol       Date:  2012-07-01       Impact factor: 4.849

8.  CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Patrick Oeckl; Petra Steinacker; Stefan Lehnert; Sarah Jesse; Hans A Kretzschmar; Albert C Ludolph; Markus Otto; Boris Ferger
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

Review 9.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870

Review 10.  Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis.

Authors:  Dan Xie; Ling Feng; Hongyan Huang; Quanzhen Zhao; Pingping Ning; Qiuyan Shen; Haitao Lu; Fang Xu; Yanming Xu
Journal:  Behav Neurol       Date:  2021-05-31       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.